Glucotrace

Glucotrace is a radiopharmaceutical solution for injection that contains the active ingredient fludeoxyglucose (18F). It is supplied without a specified strength and is administered intravenously under prescription. As a diagnostic PET imaging agent, Glucotrace acts as a glucose analog that highlights metabolic activity in tissues, enabling clinicians to assess oncologic, cardiac, and neurologic conditions through positron emission tomography.

Glucotrace is employed in several PET imaging applications to evaluate metabolic activity in the body. It assists physicians in diagnosing and managing a range of conditions.

- Oncologic PET imaging for tumor detection, staging, and treatment response assessment. - Cardiac PET imaging to evaluate myocardial viability and perfusion. - Neurologic PET imaging for brain metabolism studies, including dementia and epilepsy evaluation. - Research studies investigating glucose metabolism in various disease models. - Companion diagnostic use when paired with targeted therapies.

Adverse reactions to Glucotrace are generally infrequent but may occur following intravenous administration. Most events are mild and transient.

Common: - Mild injection site discomfort or erythema. - Transient nausea or vomiting. - Temporary headache. - Low-grade fever. - Mild allergic skin reactions such as urticaria.

Serious: - Anaphylactic or severe hypersensitivity reactions. - Significant hypotension or cardiovascular collapse. - Acute renal impairment in susceptible patients. - Severe radiation‑related tissue injury (rare with standard dosing).

Glucotrace should be used with careful consideration of patient‑specific factors and procedural protocols. Key safety points include: - Verify patient identity and confirm indication before administration. - Assess renal function, especially in patients with known impairment. - Use appropriate radiation protection measures for staff and surrounding individuals. - Pregnant or breastfeeding patients should be evaluated for risk versus benefit, as fetal exposure is unknown. - Ensure proper handling and disposal of radioactive waste according to local regulations. - Monitor patients for immediate adverse reactions during and after injection.

Glucotrace may interact with other substances that affect glucose metabolism or radiation exposure. Consider the following:

Avoid: - Concurrent administration of high‑dose glucose or dextrose solutions that could compete for cellular uptake. - Use of other radiopharmaceuticals within 24 hours that may increase cumulative radiation dose.

Use with caution: - Medications that alter blood glucose levels (e.g., insulin, oral hypoglycemics) as they may affect tracer distribution. - Contrast agents used in CT imaging performed immediately before or after PET, which could affect image interpretation. - Drugs that influence renal clearance, potentially modifying tracer elimination.